$1.75
-0.03[-1.69%]
At close: Apr 19
$1.75
0[0.00%]
After Hours: 4:09PM EDT
eFFECTOR Therapeutics
(NASDAQ:EFTR)eFFECTOR Therapeutics Stock (NASDAQ:EFTR), Analyst Ratings, Price Targets, Predictions
eFFECTOR Therapeutics Inc has a consensus price target of $17.92, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on March 28, 2024, February 6, 2024, and November 14, 2023. With an average price target of $17.67 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 909.52% upside for eFFECTOR Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Stifel
Credit Suisse
JMP Securities
Mizuho
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for eFFECTOR Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/28/2024 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 1271.43% | HC Wainwright & Co. | Robert Burns | → $24 | Reiterates | Buy → Buy | Get Alert |
| 02/06/2024 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 1271.43% | HC Wainwright & Co. | Robert Burns | $5 → $24 | Maintains | Buy | Get Alert |
| 11/14/2023 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 185.71% | HC Wainwright & Co. | Robert Burns | → $125 | Reiterates | Buy → Buy | Get Alert |
| 08/24/2023 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 185.71% | HC Wainwright & Co. | Robert Burns | → $125 | Initiates | → Buy | Get Alert |
| 05/26/2023 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 300% | Stifel | Benjamin Burnett | $32.5 → $175 | Upgrade | Hold → Buy | Get Alert |
| 05/10/2023 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 214.29% | Credit Suisse | Judah Frommer | $175 → $137.5 | Maintains | Outperform | Get Alert |
| 03/09/2023 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 300% | Credit Suisse | Judah Frommer | $200 → $175 | Maintains | Outperform | Get Alert |
| 01/09/2023 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | -42.86% | JMP Securities | Reni Benjamin | $50 → $25 | Maintains | Market Outperform | Get Alert |
| 01/06/2023 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 357.14% | Credit Suisse | Judah Frommer | $250 → $200 | Maintains | Outperform | Get Alert |
| 11/17/2022 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 14.29% | JMP Securities | Reni Benjamin | $125 → $50 | Maintains | Market Outperform | Get Alert |
| 08/11/2022 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 185.71% | JMP Securities | Reni Benjamin | $200 → $125 | Maintains | Market Outperform | Get Alert |
| 03/17/2022 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 700% | Credit Suisse | Judah Frommer | $400 → $350 | Maintains | Outperform | Get Alert |
| 01/25/2022 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 814.29% | Credit Suisse | Judah Frommer | $500 → $400 | Maintains | Outperform | Get Alert |
| 01/25/2022 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 254.29% | Stifel | Benjamin Burnett | $500 → $155 | Downgrade | Buy → Hold | Get Alert |
| 01/25/2022 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 357.14% | JMP Securities | Reni Benjamin | $825 → $200 | Maintains | Market Outperform | Get Alert |
| 11/09/2021 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 1042.86% | Stifel | Benjamin Burnett | → $500 | Upgrade | Hold → Buy | Get Alert |
| 10/12/2021 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 1042.86% | Credit Suisse | Judah Frommer | → $500 | Initiates | → Outperform | Get Alert |
| 10/04/2021 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 1042.86% | Mizuho | Mara Goldstein | → $500 | Initiates | → Buy | Get Alert |
| 09/21/2021 | EFTR | Buy Now | eFFECTOR Therapeutics | $1.75 | 1785.71% | JMP Securities | Reni Benjamin | → $825 | Initiates | → Market Outperform | Get Alert |
FAQ
What is the target price for eFFECTOR Therapeutics (EFTR)?
The latest price target for eFFECTOR Therapeutics (NASDAQ: EFTR) was reported by HC Wainwright & Co. on March 28, 2024. The analyst firm set a price target for $24.00 expecting EFTR to rise to within 12 months (a possible 1271.43% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for eFFECTOR Therapeutics (EFTR)?
The latest analyst rating for eFFECTOR Therapeutics (NASDAQ: EFTR) was provided by HC Wainwright & Co., and eFFECTOR Therapeutics reiterated their buy rating.
When was the last upgrade for eFFECTOR Therapeutics (EFTR)?
The last upgrade for eFFECTOR Therapeutics Inc happened on May 26, 2023 when Stifel raised their price target to $7. Stifel previously had a hold for eFFECTOR Therapeutics Inc.
When was the last downgrade for eFFECTOR Therapeutics (EFTR)?
The last downgrade for eFFECTOR Therapeutics Inc happened on January 25, 2022 when Stifel changed their price target from $20 to $6.2 for eFFECTOR Therapeutics Inc.
When is the next analyst rating going to be posted or updated for eFFECTOR Therapeutics (EFTR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of eFFECTOR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for eFFECTOR Therapeutics was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
Is the Analyst Rating eFFECTOR Therapeutics (EFTR) correct?
While ratings are subjective and will change, the latest eFFECTOR Therapeutics (EFTR) rating was a reiterated with a price target of $0.00 to $24.00. The current price eFFECTOR Therapeutics (EFTR) is trading at is $1.75, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.